Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A Bayesian design and analysis for dose-response using informative prior information.

Michael K Smith1, Scott Marshall

  • 1Pharmacometrics, Pfizer Global Research and Development, Sandwich, Kent, UK. Mike.K.Smith@Pfizer.Com

Journal of Biopharmaceutical Statistics
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of a conceptual model to predict physical activity identity among Canadian adults.

British journal of health psychology·2026
Same author

Pharmacometric Model-Based Sample Size Allocation for a Region of Interest in a Multi-Regional Phase 2 Trial: A Case Study of an Anti-Psoriatic Drug.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Incorporating Multiple Imputation Into Tanezumab Dose-Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo-Controlled Phase 3 Trials.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating <i>TP53</i> Wild-Type Chronic Lymphocytic Leukemia.

Cancers·2025
Same author

Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus.

British journal of clinical pharmacology·2024
Same author

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Blood advances·2024
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study uses Bayesian methods to incorporate prior drug information into new dose-response studies. This approach efficiently estimates relative potency, even with smaller sample sizes, for new drug candidates.

Area of Science:

  • Pharmacology
  • Biostatistics
  • Drug Development

Background:

  • Leveraging existing drug data is crucial for efficient new drug development.
  • Bayesian methodology offers a quantitative framework to integrate prior information.
  • Dose-response studies are essential for characterizing drug efficacy and safety.

Purpose of the Study:

  • To utilize prior information from an existing drug to inform the design and analysis of a dose-response study for a new drug candidate.
  • To employ Bayesian methodology for quantitative integration of prior knowledge and weighted randomization.
  • To establish the relative potency between a new compound and existing drug therapy.

Main Methods:

  • An Emax model was used to characterize the dose-response of the existing drug.

Related Experiment Videos

  • Estimates from the Emax model provided informative prior distributions for the new study.
  • Bayesian inference was applied for the design and analysis, assuming data exchangeability.

    • Main Results:

    • Simulations demonstrated that modest sample sizes can yield informative results on relative potency.
    • The approach allows for weighted randomization favoring the new compound where information is limited.
    • Operating characteristics were favorable when assessing model estimates against clinically significant changes in relative potency.

    Conclusions:

    • Bayesian methodology effectively integrates prior drug information into new dose-response studies.
    • This approach enhances the efficiency of relative potency estimation for new drug candidates.
    • The method provides a robust framework for drug development, particularly when data is scarce.